Tolerance Bio: $17.2 Million (Seed) Raised To Increase Healthspan By Manipulating Thymus Functions
By Amit Chowdhry ● Oct 29, 2024
Tolerance Bio, a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, announced the closing of its oversubscribed $17.2 million seed funding round, led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners and individual biotechnology investors.